News | December 31, 2019

Principia Updates PRN1008 Pemphigus Clinical Program Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021 SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq:...

News | May 20, 2019

PRINCIPIA PRESENTS PHASE 1 DATA OF PRN1371 IN PATIENTS WITH METASTATIC BLADDER CANCER — FGFR inhibitor PRN1371 well tolerated in 36 patients in dose-escalation phase; dose expansion in metastatic urothelial carcinoma patients ongoing — SOUTH SAN FRANCISCO,...

News | March 2, 2019

PRINCIPIA BIOPHARMA ANNOUNCES POSITIVE DATA FROM PHASE 2 PEMPHIGUS VULGARIS TRIAL AT 2019 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING IN LATE-BREAKING PRESENTATION Reached primary endpoint of Control of Disease Activity at four weeks in 54 percent of patients on...